BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
BSEM Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
BioStem Technologies, Inc.NASDAQ: BSEM
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to -113.6%
Net margin was -113.6% in Q2 FY2026, down 112.4 pp from a year earlier. On a trailing-twelve-month basis it was 46.9%, up 38.4 pp year over year. Over 3 fiscal years it widened by 89.0 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 1 analysts of -110.6% for the fiscal year ending Dec 2026, down from -13.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -113.6%+30.2 pp QoQ
- Last fiscal yearDec 2025
- -13.9%-24.4 pp YoY
- LTMJun 2026
- 46.9%+38.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -112.4 pp | -111.2 pp | +1.2 pp |
| 1 year | -24.4 pp | -96.7 pp | -72.3 pp |
| 3 years | +89.0 pp | +12.1 pp | -77.0 pp |
| 5 years | +22.4 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -13.9%
- Year-over-year change
- -24.4pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -13.9% | -24.4pp |
| FY2024 | 2024-12-31 | 10.6% | +61.4pp |
| FY2023 | 2023-12-31 | -50.8% | +52.1pp |
| FY2022 | 2022-12-31 | -102.9% | -69.6pp |
| FY2021 | 2021-12-31 | -33.3% | — |
Net Margin vs competitors
How BSEM compares with its peers on the latest reported figures
No competitor Net Margin figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.34M | 6.88M | 16.69M | 301.83M | 47.48M |
| Cost of Revenue | 1.47M | 881.75K | 1.26M | 13.75M | 3.26M |
| Gross Profit | 2.87M | 5.99M | 15.42M | 287.86M | 44.22M |
| Gross Margin | 66.0% | 87.2% | 92.4% | 95.4% | 93.1% |
| Research & Development | 119.65K | 123.31K | 342K | 1.91M | 7.09M |
| Selling, General & Admin | 4.19M | 10.21M | 22.63M | 254.75M | 37.82M |
| Operating Expenses | 4.47M | 10.67M | 23.2M | 256.66M | 44.91M |
| Depreciation & Amortization | 283.9K | 243.42K | 229.02K | 293.22K | 219.42K |
| EBITDA | (602K) | (6.52M) | (7.55M) | 31.49M | (469.73K) |
| EBITDA Margin | -13.9% | -94.8% | -45.3% | 10.4% | -1.0% |
| Operating Income | (1.61M) | (4.68M) | (7.78M) | 31.2M | (689.15K) |
| Operating Margin | -37.0% | -68.1% | -46.6% | 10.3% | -1.5% |
| Interest Income | 0 | 0 | 0 | 0 | 413.85K |
| Interest Expense | 525.88K | 468.15K | 700.33K | 587.22K | 0 |
| Other Income / Expenses | 193.93K | (2.55M) | (704.02K) | (587.22K) | 299.5K |
| Income Before Tax | (1.41M) | (7.11M) | (8.48M) | 30.61M | (389.65K) |
| Pre-Tax Margin | -32.5% | -103.5% | -50.8% | 10.1% | -0.8% |
| Income Tax Expense | 0 | 0 | 0 | (1.27M) | 6.19M |
| Net Income | (1.45M) | (7.07M) | (8.48M) | 31.88M | (6.58M) |
| Net Margin | -33.3% | -102.9% | -50.8% | 10.6% | -13.9% |
| EPS (Basic) | (0.12) | (0.62) | (0.62) | 1.95 | (0.39) |
| EPS (Diluted) | (0.12) | (0.62) | (0.62) | 1.47 | (0.39) |
| Weighted Avg Shares | 11.69M | 11.41M | 13.71M | 16.37M | 16.73M |
| Weighted Avg Shares (Diluted) | 11.69M | 11.41M | 13.71M | 21.7M | 16.73M |
BioStem Technologies, Inc.
NASDAQ:BSEM
Intrinsic Alpha fair value
Locked
Current Price
$3.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.